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PREFACE 
 
Student’s Role 
  
Overall contribution and value added to projects 
My involvement was to extend a sound understanding of the theory and methods used 
in the projects. Both projects provided me a balance between theory and practical issues. 
I prepared the data for analyses, conducted the statistical analyses, presented and 
interpreted the results, and wrote up the reports. Under the supervision at each stage of 
the projects, my questions and feedback were adequately addressed. 
 
Reflections on Learning 
Both projects provided good experience for me to build on what I had learnt through the 
BCA coursework units. Project A (the effect of intervention trial) provided me a good 
opportunity to obtain practical experience in the management and analysis of data using 
the statistical software STATA. Since this was my first encounter with clinical trail data 
and my first experience with a factorial design, I was encouraged to learn about both of 
these concepts and the most common approach for analysis (for a 2x2 factorial). Project 
B (a simulation exercise) provided a project to develop theoretical knowledge and 
required a sound understanding of survival data. This project compared two models in 
the analysis of time-to-event outcomes. The principle and method used in Project B 
extended the material covered in Survival Analysis (SVA) unit, and I found that writing 
programmes to generate the simulated data and the censored data was a challenge for 
me. This project afforded me with experience in the use of simulations to develop theory. 
I had a better understanding the characteristics of an exponential distribution of survival 
times with censored observations and the censoring mechanism with its influence on the 
model selection and interpretation. Overall, my knowledge and skills learnt in both 
projects were extended and the experience was invaluable. 
 
Communication skills 
During these projects I would discuss any problem and obtain advice from my 
supervisors.  This meant that I had regular face-to-face meetings with both supervisors, 
as well as communication via email. 
 
Work patterns/planning 
These projects were undertaken outside my normal working hours. Time management 
was a challenge to me. Most of time, I had weekly meetings to discuss the Project A 
progress with my supervisor. This project was broken into smaller tasks and regularly 
reviewed to provide clear planning objectives and continuously review the project 
progress. Project B started later than Project A, a whole idea was discussed at the 
beginning and developed during the time. However, my supervisor provided me extra 
time for discussion and necessary advice when it was required.  
  
Statistical principles and statistical methods 
I was keen to take on projects which gave me opportunity to further my understanding 
of statistical principles and methods. These two projects combined both practical issues 
and theoretical topics and consolidated almost of the theory learnt through the BCA 
units which I had taken.  
 
Statistical computing 
The statistical software package STATA was used in both projects. Although I have been 
using STATA in some BCA units, I was still a reasonably naive STATA user prior to the 
commencement of these projects. In particular, Project B was a challenge for me, as 
writing a programme to simulate data was not easy at the beginning and I felt frustrated. 
I had to read user book and tried to get information from the relevant topics. However, 
since undertaking these projects, I have become more familiar with STATA and feel 
comfortable now with its programming. 
 
Consolidation of BCA knowledge 
Both projects required the knowledge and skills gained through the BCA units. Without 
any background and previous experience in mathematics and clinical trials, I improved 
the learning process through these projects, which helped to ties some of the BCA units 
together. When I encountered problems, I tried to read the course notes to seek the 
background knowledge and possible solutions (or at least directions for solutions). 
Project A involved regression modeling in a clinical trial setting, which used the 
knowledge and skill gained from several BCA units. Project B consolidated my 
understanding of survival data, which I had gained from SVA. 
 
Teamwork 
I was undertaking both projects directly supervised by the project supervisors only. 
There was no other opportunity to involve teamwork. 
 
Ethical Considerations 
There were no major ethical considerations for both projects. For Project A, the data 
was de-identified with the use of a unique subject ID for each patient with no personally 
identifying information. Since Project B involved simulation data from a chosen 
distribution, there was no actual patient data information was used. 
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Project Title 
Evaluation of Pain Management Education Strategies in Cancer Patients 
 
Location and dates 
NHMRC Clinical Trials Centre, University of Sydney 
August, 2006-January, 2007 
 
Context 
A randomised trial was conducted to investigate if education materials are effective in 
reducing barrier behaviours against effective pain management for patients with cancer. 
Two educational interventions were assessed in a 2x2 factorial design - a video/DVD 
and a booklet. Patients were assessed on pain knowledge and attitudes, quality of life 
and anxiety. A questionnaire, known as the Barriers Questionnaire (BQ), was used to 
evaluate barrier attitudes to pain management.  
 
Contribution of Student 
The student was required to understand how to conduct the primary analysis of the 
Barrier Questionnaire data. The student carried out the related data management tasks 
that were defined by the project supervisor. The student also wrote a report describing 
the work and interpretation of results. All the calculations in this project were using 
STATA and the results were verified by SAS software. 
 
Statistical Issues 
- Selection of suitable outcome measurement  
(distribution, treat as continuous/categorical or convert to dichotomous) 
- Factorial design issues 
- Regression model including or excluding interaction 
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 1.0 BACKGROUND 
1.1 Background and Rationale 
Background 
Ferrell (1999) states that pain is an important problem for the patients with cancer.  
Pain arising from cancer affects many patients in a variety of ways and depends on 
severity and type of pain. Since pain is subjective, the knowledge and attitudes 
regarding effective pain management may have an important impact on the patient’s 
quality of life and as such, patients should be involved in their own pain management 
strategy. 
 
In this study, the Barriers Questionnaire (BQ) is used to assess obstacles in patients’ 
attitude that may hinder effective pain management. The BQ is a 27-item self-report 
question designed to measure the extent to which patients perceive particular issues 
(namely addiction, tolerance, side effect, progression of disease, fatalism, injections, 
good patient behaviors and distraction of doctor) as potential barriers to pain 
management. Each issue is assessed through a number of questions, with a mean score 
obtained for each subscale issue and a total mean score evaluated over all questions on 
the Barrier Questionnaire. The Barriers Questionnaire was used by Ward (1993) to 
assess the extent to which patients have concerns about reporting pain and using pain 
medication. Ward found that there was an inverse relationship between education level 
and the total score measured from the Barriers Questionnaire, suggesting that pain 
education can be effective in improving the pain management in the patients with cancer. 
Additionally, higher BQ scores were related to higher pain levels, indicating changes in 
pain levels reflect in the BQ scores due to the impact of the pain education.  
 
Rationale 
The investigators for this study wished to determine if specific educational interventions 
would improve pain knowledge and attitudes, quality of life and anxiety in patients with 
pain due to advanced cancer compared with standard care. If there is significant 
improvement on patients’ perceptions of barriers towards effective pain management 
when educational strategies are employed, the educational interventions could be 
implemented for all cancer patients to optimize effect pain management. 
 
1.2 Objectives and Aims 
The aims for this project were to determine if an educational intervention improves 
perceptions regarding pain management compared with standard care, specifically with 
respect to: 
a. an educational booklet and/or 
b. an educational video/DVD 
 
The primary outcome was measured through the Barrier Questionnaire (BQ), a 
validated instrument designed to measure knowledge and attitudes to pain. From this 
questionnaire, it is possible to obtain outcome measures for: 
 
• Total BQ score (primary outcome) 
• BQ subscales, including patient perceptions concerning: 
- addiction,  
- tolerance,  
- side effects,  
- progression of disease,  
- fatalism,  
- injections,  
- behavior of a ‘good patient’ and  
- distraction of doctors’ attention from clinical management of the disease. 
 
The Barrier Questionnaire was administered at baseline and then again two weeks and 
four weeks after baseline. The primary outcome was focused on the short-term 
responses (i.e., 2 weeks after baseline). 
 
1.3 Trial Design 
 
This study was designed as a randomized 2x2 factorial design with the following 
structure: 
 
• Factor A : Booklet versus standard care 
• Factor B : Video/DVD versus standard care  
 
Standard care is currently defined as use of no educational interventions (e.g., no 
provision of booklets, pamphlets, video/DVDs, etc). 
 
1.4 Patients  
 
Patients were recruited through oncology and radiation oncology outpatient clinics 
within New South Wales. Patients were considered eligible for the trial if they satisfied 
the following criteria:  
- metastatic or locally advanced cancer,  
- cancer pain score greater than or equal to 2/10 in the last week,  
- treated through an outpatient clinic,  
- possessed proficient English skills,  
- a survival prognosis of greater than one month (to allow for measurement of 
outcomes), 
- receiving cancer treatment at participating hospitals,  
- age greater than or equal to 18.  
 
Once eligible patients were identified, they were invited to participate and received an 
information sheet. If agreeable, patients signed the consent form and completed the 
demographic and baseline questionnaires. The first set of questionnaires was 
administered in an outpatient clinic setting so that patients were provided with standard 
instructions and guidance for completing the forms. Subsequent questionnaires were 
able to be completed by the patient in their own home.  
 
In this randomized study, there were 217 patients recruited and randomized into four 
treatment groups: (a) standard care; (b) video/DVD alone; (c) booklet alone; or 
(d) video/DVD+ booklet.  
 
There were 140 patients who completed questionnaires at both week 0 (baseline), week 
2 and week 4, with an additional 16 patients completing the questionnaires at only week 
0 and week 2. Therefore, the data of those 156 patients were assessed with respect to the 
short-term changes in total BQ score (primary outcome) and for the eight BQ subscale 
scores. There were 61 patients who were randomized but not included in the analysis 
due to missing follow-up data. These patients were evenly balanced between the four 
treatment groups and had reasonably similar baseline characteristics, suggesting no 
systematic bias due to treatment allocation for missing follow-up data. 
 
 
2.0 METHODS 
 
2.1 A randomized 2x2 factorial design 
 
Theory 
Steven Piantadosi (1997) states that “Factorial clinical trials are experiments that test the 
effect of more than one treatment using a design that permits an assessment of 
interactions among the treatments.” When conducting a trial with a factorial design, 
there are two classes of effects that need to be considered, which include interactions 
between the factors versus the main effects of the factors tested. In a standard 2x2 
factorial design, we consider the effects of factor A and factor B in the following 
context: 
- Whether there is evidence of an interaction between the two factors, implying 
that the effect of factor A depend on the levels (presence/absence) of factor B 
(i.e., the combination of effects is multiplicative, which is more/less than the 
expected sum of the separate effects). 
- In the absence of an interaction, whether there is evidence of an effect for factor 
A and/or factor B. If these two factors are independent, the combined effects of 
factor A and factor B will equal the simple sum of the separate effects of factor 
A and factor B (the combination of effects is additive). 
 
We can apply linear modeling techniques to estimate the main effects of the factors and 
their interactions of factor A and factor B. The form of the linear model is presented as 
below: 
   BAABBBAA XXXXYE ββββ +++= 0}{  
Where AX and BX  are representative for the individual factors A and B, BA XX  is the 
interaction term of factor A and factor B. The coefficients of Aβ , Bβ  and ABβ  represent 
the effects of factor A, factor B and the interaction effect of factor A and factor B on the 
outcome. 
Trial Application 
For our trial, we used regression models to examine the effects of the two factors 
(booklet, video/DVD). To begin with, we examined whether there was evidence of an 
interaction effect between the two treatment factors. If there was no evidence of a 
significant interaction (at the 5% level), the main effects were addressed in another 
model omitting the inclusion of an interaction term.  
 
As there were four treatment groups in this study (standard care; video/DVD alone; 
booklet alone; or video/DVD + booklet), the following binary indicators were used to 
code the two factors:  
 
- When the treatment groups were video/DVD alone or video/DVD plus booklet, 
the binary indicator for Video/DVD was set to 1; when the treatment groups 
were booklet alone or standard care, it was coded as 0. 
- When the treatment groups were booklet alone or video/DVD plus booklet, the 
binary indicator for Booklet was set to 1; when the treatment groups were 
video/DVD alone or standard care, it was coded as 0. 
 
As a result, we fitted the following two models, including or excluding the interaction 
between booklet and video/DVD, and the results of these two models were assessed. 
 
- Model 1: including interaction 
{ } )()/()*/()()()/()/(0 BookletDVDVideoBookletDVDVideoBookletBookletDVDVideoDVDVideo XXXXYE ββββ +++=
 
- Model 2: excluding interaction 
{ } )()()/()/(0 BookletBookletDVDVideoDVDVideo XXYE βββ ++=  
 
 
 
  
2.2 Selection of appropriate outcome for analysis 
 
When applying standard linear regression models, it is assumed that the deviations of 
individual values around the mean value will be modeled as arising from a Normal 
probability distribution. In this study, the total BQ score and the corresponding BQ 
subscales at week 0 and week 2 were skewed, and as such, the error distribution was not 
normally distributed. This is a violation of one of the fundamental assumptions of the 
regression model and as such, any inference made from such model may be incorrect. 
However, it was observed that the change in BQ score between week 2 and week 0 were 
normally distributed (less skewed), with residuals following a Normal distribution after 
a linear model was imposed. As a result, it was decided to use the change in BQ scores 
(week 2 - week 0) as the outcome for the following analyses. An example of the 
distribution of total BQ scores at week 0, week 2 and its difference at (week 2 - week 0) 
is shown in Figure 2.2.1 
 
Figure 2.2.1 The distribution of total BQ score at week 0, week 2 and its difference for  
(week 2 - week 0) 
 
 
  
3.0 RESULTS 
 
3.1 The summary of baseline characteristics of the treatment groups 
 
The baseline data were collected once the eligible patients were identified and before 
the patients were randomly allocated to the treatment groups. If the randomization has 
been conducted correctly, the study groups should be similar in baseline characteristics 
(except for the play of chance). The baseline data included age, sex, type of cancer, the 
year first diagnosed, highest education level, marital status, country of birth and the first 
language are presented in Table 3.1.1. The patients had an average age of 62 years. 
There was higher percentage of female patients (57%) than male patients (42%) in the 
study. The major types of cancer were breast cancer (26%) and lung cancer (19%). The 
majority of patients (73%) were first diagnosed with cancer after 2000 year and 63% 
patients were married. There were 30% patients who had completed university/tertiary 
study, with around 76% patients born in Australia and 92% patients using English as 
their first language. The four treatment groups appeared reasonably similar in the 
distribution of these baseline characteristics, particularly when considering the small 
sample size of each group. Hence, in our study we did not include the baseline 
covariates in the model. 
 
Table 3.1.1 The baseline characteristics of the treatment groups 
Baseline 
Characteristics 
Standard 
Care 
(n=38) 
Booklet 
(n=36) 
Video/DVD 
(n=37) 
Video/DVD 
& 
Booklet 
(n=45) 
 
Total 
(N=156) 
Age: Mean (Std. Dev) 60.5 (12.0) 61.9 (12.3) 62.3 (15.3) 63.1 (11.6) 62.0 (12.7) 
    Median [Q1, Q3] 61 [52, 69] 63 [53, 72] 66 [51, 74] 63 [56, 71] 63 [54, 71] 
[Min, Max] [29, 88] [34, 89] [26, 87] [36, 86] [26, 89] 
Sex:   Female 22 (56%) 20 (56%) 25 (69%) 22 (49%) 89 (57%) 
Male 16 (41%) 16 (44%) 11 (31%) 23 (51%) 66 (42%) 
Type of Cancer  
Bowel 4 (10%) 2 (6%) 2 (6%) 3 (7%) 11 (7%) 
Breast 9 (23%) 8 (22%) 14 (39%) 9 (20%) 40 (26%) 
Genito-Urinary 3 (8%) 2 (6%) 3 (8%) 6 (13%) 14 (9%) 
Prostate 5 (13%) 3 (8%) 2 (6%) 7 (16%) 17 (11%) 
Skin 6 (15%) 6 (17%) 6 (17%) 4 (9%) 22 (14%) 
Lung/Mesothelioma 6 (15%) 9 (25%) 5 (14%) 9 (20%) 29 (19%) 
Other 4 (10%) 4 (11%) 3 (9%) 6 (13%) 17 (11%) 
Year first diagnosed  
<2000 year 12 (31%) 10 (28%) 12 (33%) 7 (16%) 41 (26%) 
≥2000 year 26 (67%) 26 (72%) 24 (67%) 38 (84%) 114 (73%) 
Highest Education  
No certificate 7 (18%) 10 (28%) 8 (22%) 8 (18%) 33 (21%) 
Junior certificate 8 (21%) 9 (25%) 6 (17%) 13 (29%) 36 (23%) 
Senior certificate 8 (21%) 4 (11%) 3 (8%) 5 (11%) 20 (13%) 
TAFE/Trade 3 (8%) 3 (8%) 5 (14%) 5 (11%) 16 (10%) 
University/Tertiary  11(28%) 9 (25%) 14 (39%) 13 (29%) 47 (30%) 
Marital Status  
Single 2 (5%) 2 (6%) 3 (8%) 1(2%) 8 (5%) 
Married 24 (62%) 27 (75%) 20 (56%) 28 (62%) 99 (63%) 
De facto 3 (8%) 1 (3%) 6 (17%) 4 (9%) 14 (9%) 
Separated or divorced 5 (13%) 3 (8%) 3 (8%) 6 (13%) 17 (11%) 
Widowed 4 (4%) 3 (8%) 4 (11%) 5 (11%) 16 (10%) 
Country of Birth  
Australia 30 (77%) 28 (78%) 28 (78%) 33 (73%) 119 (76%) 
Other 8 (21%) 8 (22%) 8 (22%) 11(24%) 35 (22%) 
First Language  
English 36 (92%) 35 (97%) 33 (92%) 40 (89%) 144 (92%) 
Other 2 (5%) 1 (3%) 3 (8%) 4 (9%) 10 (6%) 
 
3.2 Assessment of the effect of video/DVD/booklet on the total BQ score and the BQ 
subscales changes between week 2 and week 0 (baseline) 
 
To determine the effect of a video/DVD and/or booklet intervention on pain barrier 
issues for the changes of the total BQ score and the BQ subscales of addiction, tolerance, 
side effect, progression of disease, fatalism, injections, good patient behaviors and 
distraction of doctor, a linear regression model was fitted, including and excluding an 
interaction term for the two factors (Video/DVD*Booklet). If there was little evidence 
of an interaction between the two factors (tested at the conventional 5% level), the 
model fitted with main effects only was then considered. The results from these 
analyses are shown in Table 3.2.1 and Table 3.2.2 
 
Table 3.2.1 Model results for change in the total BQ score and BQ subscales (week 2-week 0) 
when including an interaction term for the two factors  
Change in Outcome 
(week 2-week 0) 
Covariate Coefficient   
(95% CI) 
P-value 
Video/DVD -0.08 (-0.36, 0.20) 0.57 
Booklet 0.02 (-0.26, 0.29) 0.91 
Total BQ 
Video/DVD * Booklet -0.0005 (-0.38, 0.38) 0.99 
Video/DVD -0.78 (-1.36, -0.20) 0.009 
Booklet -0.49 (-1.08, 0.09) 0.10 
Addiction 
Video/DVD * Booklet 0.87 (0.068, 1.68) 0.034 
Video/DVD -0.39 (-0.88, 0.11) 0.12 
Booklet 0.07 (-0.43, 0.56) 0.79 
Tolerance 
Video/DVD * Booklet 0.33 (-0.36, 1.01) 0.35 
Video/DVD -0.06 (-0.47, 0.35) 0.77 
Booklet -0.03 (-0.45, 0.38) 0.88 
Side effects 
Video/DVD * Booklet 0.13 (-0.44, 0.70) 0.66 
Video/DVD 0.21 (-0.31, 0.73) 0.42 
Booklet -0.07 (-0.58, 0.45) 0.80 
Progressive disease 
Video/DVD * Booklet -0.51 (-1.23, 0.21) 0.16 
Video/DVD -0.16 (-0.55, 0.24) 0.43 
Booklet 0.04 (-0.35, 0.44) 0.84 
Fatalism 
Video/DVD * Booklet -0.10 (-0.65, 0.45) 0.72 
Video/DVD 0.16 (-0.29, 0.61) 0.47 
Booklet -0.22 (-0.66, 0.23) 0.34 
Injections 
Video/DVD * Booklet -0.04 (-0.65, 0.58) 0.91 
Video/DVD 0.14 (-0.32, 0.60) 0.55 
Booklet 0.02 (-0.44, 0.48) 0.93 
Good patients 
Video/DVD * Booklet 0.05 (-0.59, 0.69) 0.88 
Video/DVD 0.08 (-0.38, 0.54) 0.73 
Booklet 0.08 (-0.38, 0.54) 0.73 
Distract Dr. 
Video/DVD * Booklet -0.12 (-0.76, 0.52) 0.72 
 
 
  
  
 
 
 
 
Table 3.2.2 Model results for change in the total BQ score and BQ subscales (week 2-week 0) 
when excluding an interaction term for the two factors  
Change in Outcome 
(week 2-week 0) 
Covariate Coefficient   
(95% CI) 
P-value
Video/DVD -0.08 (-0.27, 0.11) 0.41 Total BQ 
Booklet 0.01 (-0.17, 0.20) 0.88 
Video/DVD -0.33 (-0.74, 0.08) 0.11 Addiction 
Booklet -0.03 (-0.44, 0.37) 0.87 
Video/DVD -0.22 (-0.56, 0.12) 0.21 Tolerance 
Booklet 0.24 (-0.11, 0.58) 0.17 
Video/DVD 0.005 (-0.28, 0.29) 0.97 Side effects 
Booklet 0.04 (-0.25, 0.32) 0.81 
Video/DVD -0.05 (-0.41, 0.31) 0.77 Progressive disease 
Booklet -0.33 (-0.69, 0.03) 0.07 
Video/DVD -0.21 (-0.48, 0.07) 0.14 Fatalism 
Booklet -0.01 (-0.28, 0.26) 0.93 
Video/DVD 0.14 (-0.16, 0.45) 0.35 Injections 
Booklet -0.23 (-0.54, 0.07) 0.13 
Video/DVD 0.16 (-0.15, 0.48) 0.31 Good patients 
Booklet 0.04 (-0.27, 0.36) 0.79 
Video/DVD 0.02 (-0.30, 0.34) 0.91 Distract Dr. 
Booklet 0.02 (-0.30, 0.34) 0.91 
 
 
For the short-term changes in total BQ score (week 2 - week 0) and the short-term 
changes in most of the BQ subscales (e.g., tolerance, side effect, progression of disease, 
fatalism, injections, good patient behaviors and distraction of doctor), there was little 
evidence of an interaction between video/DVD and booklet treatments (all p> 0.05 for 
the interaction terms, Table 3.2.1). Furthermore, even after excluding the possible 
interaction, the results indicated that there was little evidence to suggest a benefit of 
either video/DVD or booklet for patients’ total BQ score or for the other BQ subscales 
of tolerance, side effect, progression of disease, fatalism, injections, good patient 
behaviors and distraction of doctor (all p>0.05, Table 3.2.2). 
 
However, for the change in the addiction BQ subscale (week 2 - week 0), there was 
evidence of an interaction between video/DVD and booklet treatment (p= 0.034), which 
indicates that these two factors (video/DVD and booklet) are not independent. Hence 
we need to compare the effect of the treatments against standard care (no intervention). 
It should be noted that some caution is required to interpret this conclusion in view of 
the multiple comparisons/tests that have been conducted. Keeping this in mind, the 
result is investigated further. Table 3.2.3 presents the results for each of the four 
treatment groups. The corresponding graph (Figure 3.2.1) indicates that the change in 
the addiction BQ subscale depends on the specific combination of treatment 
interventions (booklet alone, video/DVD alone, or the combination of booklet and 
video/DVD). From observation, if the subject received video/DVD treatment only 
(compared to standard care treatment), it appeared that the subject could obtain the most 
benefit in reducing the barrier perception of addiction. If the subject received booklet 
treatment only, there appeared to be a smaller reduction in the addiction subscale. It was 
good to have either video/DVD or booklet treatment, however, the combination of 
video/DVD and booklet appeared to have less of reduction in the addiction subscale 
when compared with video/DVD or booklet treatment alone. 
 
Table 3.2.3 Descriptive statistics for the BQ Addiction subscale at week 0 and week 2 
Treatment 
Group 
Week 0 (95% CI) Week 2 (95% CI) 
Mean change for 
(week 2-week 0)(95% CI)
Standard Care 1.577 (1.130, 2.033) 1.757 (1.316, 2.198) 0.180  (-0.222, 0.582) 
Booklet 1.781 (1.334, 2.229) 1.467 (1.043, 1.891) -0.314  (-0.727, 0.099) 
Video/DVD 1.843 (1.324, 2.362) 1.241 (0.827, 1.677) -0.602  (-1.007, -0.197) 
Video/DVD & 
Booklet 
1.355 (0.983, 1.728) 1.133 (0.773, 1.494) -0.222  (-0.635, 0.191) 
Figure 3.2.1 Changes of BQ subscale for Addition for (week 2 - week 0) 
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Three comparisons were constructed to formally assess this: a) standard care versus 
booklet alone; b) standard care versus video/DVD alone; c) standard care versus booklet 
and video/DVD together. 
 
Compared to standard care treatment (no intervention), there is strong change in the BQ 
subscale of addiction for patients allocated to video/DVD treatment alone (p=0.009), 
indicating a considerable mean reduction in addiction anxiety of 0.78 when patients 
received an educational video/DVD intervention. Along similar lines, when compared 
to standard treatment of no educational intervention, there appeared to be a lessening in 
the anxiety score (mean change -0.49) when patients received an educational booklet 
alone, although this reduction was not statistically significant (p=0.10). Similarly, there 
was little evidence of a noteworthy reduction in the change of anxiety scores for 
patients who received both the booklet and the video/DVD against patient who received 
no education inventions (p=0.15).   
 
From these results (Table 3.2.3 and Figure 3.2.1), it would appear that the video/DVD is 
likely to an effective educational instrument with respect of attitudes toward drug 
addiction. This analysis suggests that the provision of an educational video/DVD will 
help to reduce patients’ concerns about drug addiction for pain management, although 
there is insufficient evidence to support the same position with respect to the provision 
of an education booklet.   
 
3.3 Visual assessment of trends in BQ score and the BQ subscales from baseline 
(week 0) to 4 weeks post-randomisation 
 
Trajectory plots were made on a random selection of patients from each of the four 
treatment groups (using a quarter of the patients, selected at random). Figure 3.3.1 and 
Figure 3.3.2 display the data graphically for the trend in BQ score and the BQ subscale 
of addiction from week 0 to week 4, respectively, the individual lines connecting the 
repeated observations over time for each patient, as displayed for each of the four 
treatment groups. As can been seen from the plots, there is substantial variation between 
patients in each treatment group and there appears little trend of BQ score changes over 
time in each treatment group. The changes monitored over the 4-week period were not 
investigated with statistical models as the clinical investigators were principally 
interested in the short-term changes only. 
 
Figure 3.3.1 Trajectory plot of total BQ score changes score over weeks (at 0,2 & 4) for each 
treatment group 
 
Figure 3.3.2 Trajectory plot of BQ subscale changes for addiction over weeks (at 0,2 & 4) for 
each treatment group 
 
 
3.4 Worst reported pain at baseline and two weeks post-randomisation 
 
Patients were asked to provide a daily rating of their pain on a scale of 0 to 10, where 0 
indicated no pain and 10 indicated unbearable pain. These daily pain ratings were 
summarized in 14 days intervals, where the baseline pain inventory was measured 14 
days prior to randomization and the two weeks following randomization represented the 
week 2 measurements. For each interval, the worst reported daily pain score was 
obtained from the 14 days of observations. From a patient management perspective, 
clinicians were interested if patients were scoring moderate to severe pain (i.e., pain 
scored greater than 5 out of 10) as this indicates pain high enough to require medical 
treatment (e.g., use of opioids or similar). 
 
Worst reported pain scores were re-coded into a binary variable (pain=0 if worst pain 
score ≤ 5 and pain=1 if worst pain score > 5). The baseline status regarding proportion 
of patients reporting worst pain greater than five is presented below in Table 3.4.1 and is 
similar for the treatment groups under consideration. 
 
Table 3.4.1 Baseline status (week 0) for worst reported pain score > 5 
Patients with a worst reported 
pain score > 5 Treatment group N 
n % 
Standard care 38 22 (58%) 
Booklet only 36 18 (50%) 
Video/DVD only 36 25 (69%) 
Booklet & Video/DVD 46 32 (70%) 
    
No Video/DVD 74 40 (54%) 
Video/DVD 82 57 (70%) 
    
No Booklet 74 47 (64%) 
Booklet 82 50 (61%) 
 
A similar assessment was conducted using the worst pain scores reported two weeks 
after randomisation. There was no substantial change compared to baseline. This data 
was analysed using a chi-squared test to examine the association between the worst pain 
score and the treatment groups. Table 3.4.2 displays the results among various treatment 
groups. At 2 weeks after randomisation, there was no evidence of an association 
between worst reported pain score greater than five and the four treatment groups 
(p=0.45). Similarly, there was no evidence of an association between worst reported 
pain score greater than five and video/DVD (p=0.24) or booklet (p=0.45).  
 
Table 3.4.2 Post-randomisation status (week 2) for worst reported pain score > 5 
Patients with a worst reported 
pain score > 5 Treatment group N 
n % 
χ2(df), p 
Standare care 38 16 42 
Booklet only 36 15 42 
Video/DVD only 36 21 58 
Booklet & 
Video/DVD 
46 21 46 
χ2(3)=2.67, 
p=0.45 
     
No Video/DVD 74 31 42 
Video/DVD 82 42 51 
χ2(1)=1.36, 
p=0.24 
     
No Booklet 74 37 50 
Booklet 82 36 44 
χ2(1)=0.58, 
p=0.45 
3.5 Assessment of the change in the worst pain scores between week 0 (baseline) and 
week 2 
 
Summary pain scores (such as worst reported pain) exhibited skew distributions and 
were not normally distributed. However, similar to the BQ scores, the difference in pain 
scores between week 2 and week 0 were observed to be approximately normally 
distributed and as a result, the changes were used as the outcome to assess the effect of 
booklet and/ or video/DVD on worst reported pain scores. 
 
The results of the mean changes between week 2 and week 0 for the treatment with 
video/DVD or without video/DVD and the treatment with booklet or without booklet 
are shown in Table 3.5.1. There was no evidence of an interaction between video/DVD 
and booklet interventions on changes in worst report pain score (p=0.91, see Table 
3.5.2). As such, video/DVD and booklet intervention were considered as possible 
independent influences on the change in worse pain score after 2 weeks. However, there 
was no evidence of that the change of worse pain scores between baseline (week 0) and 
a fortnight later for patients assigned to video/DVD was different to the change in pain 
scores for patients assigned to no video/DVD treatment (p=0.11). Similarly, there was 
no evidence of differences for patients allocated to a booklet intervention versus no 
booklet (p=0.40).  
 
Table 3.5.1 Descriptive statistics for the worst reported pain score at week 0 and week 2 
Treatment group Mean at Week 0 
(95% CI) 
Mean at Week 2 
(95% CI) 
Mean change  
for (week 2 - week 0) 
(95% CI) 
No Video/DVD 5.373 (4.707, 6.039) 4.819 (4.242, 5.396) -0.554 (-1.269, 0.161) 
Video/DVD 6.199 (5.659, 6.738) 4.884 (4.308, 5.461) -1.315 (-1.882, -0.747) 
No Booklet 5.727 (5.098, 6.356) 5.004 (4.445, 5.563) -0.723 (-1.282, -0.164) 
Booklet 5.879 (5.292, 6.467) 4.717 (4.128, 5.306) -1.162 (-1.864, -0.460) 
 
 
Table 3.5.2 The coefficients of the worst pain scores changed for (week 2 - week 0) with p-value 
when fitting regression model including or excluding interaction between video/DVD and 
booklet 
Change in Outcome 
(week 2 - week 0) 
Model Covariate Coefficient 
 (95% CI) 
P-value
Video/DVD -0.67 (-1.98, 0.63) 0.31 
Booklet -0.33 (-1.63, 0.98) 0.62 
including 
interaction 
Video/DVD * 
Booklet 
-0.11 (-1.92, 1.70) 0.91 
Video/DVD -0.73 (-1.63, 0.17) 0.11 
Worst pain scores 
excluding 
interaction Booklet -0.38 (-1.29, 0.52) 0.40 
 
 
DISCUSSION 
 
This 2x2 factorial design study examined whether the educational intervention 
strategies (either by a booklet and/or a video/DVD) improves barriers, behaviors and 
perceptions towards effective pain management in patients with cancer. Short-term 
changes in patient perceptions were assessed in 156 patients who had completed 
follow-up data two weeks after baseline. Patients were assessed in terms of their 
barriers/perceptions towards overall/total pain management, as well as specific attitudes 
towards perceived addiction of pain medications, pain tolerance, side effects, 
progression of disease, fatalism, injections, good patient behaviors and doctor 
distractions. The analysis indicated that there was little evidence of benefit with the use 
of the educational interventions for nearly all the pain management barriers. However, 
there was one exception observed indicating that there was some evidence of an 
improvement in attitudes concerning addiction to pain medications after the use of an 
educational intervention of video/DVD. The potential effects of the interventions were 
also investigated in terms of reported pain, although it was found that there was no 
evidence that a pain education campaign improves the worst-reported pain scores. 
 
This study was my first exposure to ‘real’ data and also my first exposure to clinical trial 
data. While the analysis approach was (relatively) simple, this project allowed me the 
opportunity to consider the statistical implications for sub-optimal trial methodology 
(such as an insufficient sample size) and analysis issues (such as multiple testing of 
multiple outcomes).  
 
In this project, analyses were conducted over 9 outcomes for pain barriers (the total BQ 
score and 8 subscales) with only one significant result observed (the addiction subscale), 
with no adjustments for multiply comparisons. This single observed significant result 
may be an artifact of an inflated Type I error rate due to the multiplicity issue (using 
multiple outcomes and multiple tests). As a result, this single significant result should be 
treated with caution. No other statistically significant results were observed which may 
support the use of a video/DVD education strategy to alleviate concerns/barriers for 
effective pain management, suggesting that this single significant result may be a 
chance occurrence.  
 
To accurately estimate the treatment effect by comparing the treatment groups, we need 
to obtain the optimal sample size in a study. Consequently, it is important to define the 
required clinical effect of the treatments or the significant treatment difference at the 
beginning of the trial design. For this study, there are two aspects we need to consider 
for the implications concerning statistical power. 
 
In order to detect whether or not a difference is statistically significant (at the 
conventional 5% level), a sufficient sample size calculation with the desired power is 
ideally required to be considered during the trial design stage. When the sample size 
was calculated in this study, there was little published information on what was 
considered a clinically relevant difference/reduction in BQ score and as such, a 
reduction of at least 20% on the total score and the subscales was (arbitrarily) chosen to 
be sufficient to consider the education intervention clinically useful. Therefore, the 
sample size calculation was based on detecting a 20% change in the total BQ score. A 
similar study was conducted in another country earlier, using a different patient setting 
(female patients with breast cancer). From this previous work, the estimated outcomes 
measures and variability in the change in the total BQ score was used for designing the 
sample size. If a trial design assumes a greater difference would be detected with a 
smaller variance, the study would be underpowered to detect a smaller true difference 
between treatments. Unfortunately in this study, the observed difference between 
treatment groups was smaller than what had been assumed and the variance was much 
greater, effectively reducing the statistical power of the study and making it unlikely 
that statistically significant results (at the 5% level) would be achieved if the 
interventions were truly effective at reducing concerns about affective pain management. 
The ability to detect significant interactions was dramatically affected, making it very 
unlikely that interactions would be detected. With hindsight, the investigators should 
have been counseled to run a small pilot study to compare their planned population 
against the previous study. 
 
One should also consider whether it was reasonable to assume that the two interventions 
could be assumed to act independently. In the trial design stage, it was assumed that 
both booklet and video/DVD treatment were independent factors with little interaction 
between these two treatments. However, after the trial was conducted and the clinicians 
were consulted, it was discovered that it was thought likely that the combination of both 
booklet and video would help patients more than simply the provision of one 
intervention alone and it was hoped that the combination of treatments would produce 
vastly greater reductions in barrier perceptions (due to the consolidation of knowledge 
provided to these patients). This sounded like the investigators were actually 
hoping/anticipating for an interaction between the two interventions. However, the trial 
was not specifically designed to investigate this aspect, limiting the usefulness of the 
trial data to provide evidence of this hypothesis. 
 
In summary, the aspects discussed above from this study demonstrate that attention to 
trial design issues is critical for useful trial results and the ability of a trial to answer a 
hypothesis. Unfortunately, this particularly trial did not approach a statistician for 
advice prior to commencement. If a well-designed study is properly designed and 
conducted, the trial is able to answer the initial question posed by the clinicians. In order 
to have a well-designed study, it is important that the clinicians communicate effectively 
and correctly with the statisticians during the stage of the study design and that this 
communication translates into a suitable design which will achieve the trial objectives. 
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APPENDIX  
 
Major STATA commands used in this study 
 
. sort sid week 
. by sid: generate diffadd=add[2]-add[1]  
. by sid: generate diffBQ=BQ[2]-BQ[1]  
/*generate the difference between week2 and week0 for the BQ subscale of addiction, repeat the 
command to generate the total BQ score and other subscales*/  
gen Video/DVD=0 if randomisation==5 | randomisation==6   
 /*generate variale Video/DVD for those subjects received video/DVD treatment*/ 
replace Video/DVD=1 if randomisation==3 | randomisation==4 
gen Booklet=0 if randomisation==4|randomisation==6   
 /*generate variable Booklet for those subjects received booklet treatment*/ 
replace Booklet=1 if randomisation==3|randomisation==5 
gen treatment=6-randomisation   /*recode the treatments to 0, 1,2,3*/ 
bysort Video/DVD: summarize diffadd difftol diffside diffpro difffat diffinj diffgood diffdis diffBQ, detail
      /*obtain the statistical description for the difference of total BQ score and 
BQ subscales in video/DVD treatment*/ 
bysort Booklet: summarize diffadd difftol diffside diffpro difffat diffinj diffgood diffdis diffBQ, detail 
/*obtain the statistical description for the difference of total BQ score and BQ subscales in booklet 
treatment*/ 
xi:regress diffadd i.Video/DVD i.Booklet i.Video/DVD*i.Booklet  
/*regression including interaction for the difference of addiction between week2 and week0, 
repeated this command in the total BQ score and other BQ subscales */ 
xi:regress diffadd i.Video/DVD i.Booklet       
/*regression excluding interaction for the difference of addiction between week2 and week0, 
repeated this command in the toal BQ score and other BQ subscales*/ 
scatter add week,by(treatment, title("The BQ score in Addiction over week=0,2&4")) c(l) 
table trt week, c(mean add)   
 /*graph the trajectory plots for the addiction subscale, repeated this command to obtain the plots for 
the total BQ score*/ 
gen code_add=0 if add<=0.5    
/*recode the addiction subscale and check the general association at baseline*/ 
replace code_add=1 if add>0.5 & add<=1.5 
replace code_add=2 if add>1.5&add<=2.5 
replace code_add=3 if add>2.5&add<=3.5 
replace code_add=4 if add>3.5&add<=4.5 
replace code_add=5 if add>4.5 & add!=. 
tabulate code_add treatment if week==0,cchi2 chi2 exact expected 
use "G:\Pain Education Study\WPP\Dataset\Pain worst.dta", clear 
 /*create the dataset for pain scores analysis*/ 
merge sid using "G:\Pain Education Study\WPP\Dataset\Randomisation.dta" 
sort sid 
sort sid week 
by sid: generate diff_painworst=pain_worst[2]-pain_worst[1] 
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1.0 BACKGROUND 
 
1.1 Overview the time to event problem 
In survival analysis of clinical studies an outcome of interest is the time to an event, 
such as the time to disease progression, subjects may not have experienced the event of 
interest during the observation period of the study. With this type of time to event data, 
for the subjects who will not have experienced the event under investigation at the time 
of analysis, the time to event is classified as being censored. Thus we do not know when 
they will experience the event, only that at the time of analysis of the trial they are still 
event free. Censoring may also occur due to the fact that the subject has left the study 
before they experience the event, or the subject is “lost to follow up” during the study, 
or the subject experienced a competing event in advance of the event of interest in the 
study. For the subjects who experienced the event in the study, a censoring indicator is 
set to the value of one, while for the censored observations this censoring indicator is 
given a value of zero. Hence, the time to event data in a study contains the times to 
event of the subjects who experienced the event of interest as well as the times to event 
of the subjects who are censored. We are interested what kind of data can estimate the 
effect of treatment on the time to event of interest.  
 
For example, in a survival study subjects are recruited over a period of 2 years (24 
months) with a further 18 months follow-up period, the overall study period being 42 
months. Figure 1.1 shows some subjects (e.g., #3, #4, #5 and #6) were observed to have 
the event of interest (denoted by X’s) during the study period. Subject #1 was not 
observed to experience the event at the end of the study. Subject #2 was lost to follow 
up before the end of study. Subjects #1 and #2 are censored (denoted by circles) as their 
event status is unknown at the time of the study period. 
 
 
 
 
 
  
   6        X 
   5                     X 
   4        X 
   3          X 
   2             
   1          
           24     48(end of study) months 
Figure 1.1 recruited, follow-up, and censoring on an event time study 
 
1.2 Interval Censoring 
In some situations, the time to event of interest may only be known to have occurred 
within some time interval. Subjects are followed up at scheduled visits but the event of 
interest may have occurred between visits, and hence, we do not know the exact time to 
the event. Consider the example in an oncology study to evaluate the time to disease 
progression in patients with advanced colorectal cancer. The tumor progression is the 
term for the gradual cellular and molecular changes that occur during the development 
of tumors (i.e., cancer cell growth, invasion and metastasis, etc). Computerised 
tomography (CT) scans are used to detect the tumor progression during the study period. 
The time to tumor progression is defined as the time from the date of the original CT 
scan to the date of tumor progression. The subject will be diagnosed as having tumor 
progression if the CT scan shows the evidence in a new tumor or the increasing size of 
the original tumor, which is indicating how deep the tumor has penetrated, whether it 
has invaded the adjacent organs, and whether it has spread to distant organs, etc. For 
those subjects who are not observed as having a new tumor, or remain the same size/ 
reduce the size of the original tumor comparing with the original CT scan, we regard 
these subjects do not have tumor progression at the end of the observation period. 
 
 Since the tumor progression of the subjects is regularly checked using CT scans at fixed 
time point (e.g., every 6 weeks until the end of study), if the tumor progression of a 
subject has not observed at one CT scan but has been deemed to have progressed at the 
next scan, the time to tumor progression will only know to be within this interval (6 
weeks) but we do not know the actual time to tumor progression for this subject. Data of 
this type is often referred to interval-censored data. For example, if the CT scan at week 
12 indicated the subject without tumor progression but the next scan at week 18 was 
showing progression indicating tumor progression having occurred between week 12 
and week 18. Standard methods to analyse such data assume that the event occurred at 
the end of interval. In this situation, such analysis would set the time to tumor 
progression at week 18. This raises the question as to the setting of the event time to the 
time of assessment (i.e., follow-up visits) will have impact on the estimates of the 
hazard ratio.  
 
1.3 Objectives 
To investigate the question mentioned above, we performed a simulation study to 
compare the estimates of the hazard ratio using: 
 
- The original times to disease progression (which were known from the 
simulated data); 
- A time to event analysis (Cox proportional hazards model) where the subjects’ 
time to disease progression were recorded as at the time of visit when the CT 
scan was performed; 
- An interval-censored approach (interval-censored proportional hazards model) 
where the subjects who were identified as having disease progression at a 
scheduled scan were assumed to have failed in the interval between their 
previous scan and the current scan. 
 
 
 
2.0 METHODS 
 
The exponential distribution is often used to model survival data (i.e., time to disease 
progression with censored observations). We will assume that the times to disease 
progression follow an exponential distribution for our investigation. The exponential 
distribution has density function: 
  xexf λλλ −=),(   )0( ≥x    (1) 
Where λ  is a rate of failure per unit time (i.e., in our case, the number of failures per 
month), the exponential variable x is the time to disease progression (i.e., in our case, it 
is measured in months) of a random subject from the population. The exponential 
distribution is unique in that it has a constant hazard rateλ . 
In order to generate the times to event (disease progression) of subjects from an 
exponential distribution with a hazard rateλ , we need to find a relationship between 
uniform (0,1) random number ))1,0((U and the exponential distribution. Hence, this is 
required to transfer the U (0,1) random number into the form of f ( λ,x ). If we find 
the cumulative distribution function of the exponential distribution F(x,λ), we know that 
this lies between 0 and 1 as F(0,λ) =0, F(∞,λ) = 1. Now, if given a random variable U  
drawn from the uniform distribution on the unit interval (0,1), by using inverse 
transformation of the cumulative distribution function we can obtain the corresponding 
exponential variable x . The exponential distribution with different hazard rateλ  will 
give different cumulative distribution function. The cumulative distribution function is 
determined by integrating formula (1) 
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In order to get the exponential variable x  from the cumulative distribution function, 
we simply use formula (2) to obtain  
xeU λ−−= 1    (3) 
Then the exponential variable is 
  λ
)1ln( Ux −−=   (4) 
If we generate iU  variable from U (0, 1), we can then create the exponential variable 
ix  for any fixedλ  using the relationship   
  λ
)1ln( i
i
U
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We use a two-arm randomised trial (colorectal cancer example) to evaluate the time to 
disease progression in patient tumor. We know that group 1 (control group) has a 
median time to tumor progression of 12 months. Now if a new treatment used in group 
2 (treatment group) can change this median time to tumor progression to 18 months 
with a recruitment period of 24 months and an 18 months follow-up period (42 months 
for the overall study period). We assume the time to tumor progression follows an 
exponential distribution with a fixed hazard rateλ ; hence, the original times to tumor 
progression can be generated by using formula (5) with a fixed hazard rateλ . Before we 
generate the original time to tumor progression we need to know the hazard rateλ  for 
each group. As the median time to tumor progression )(mediant  is given in this study, this 
is the time to tumor progression at which the cumulative distribution function is equal to 
0.5, then the relationship between the median time to tumor progression )(mediant  andλ  
can be obtained from formula (2) 
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When x is equal to the median time to tumor progression ( x = )(mediant ) 
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Then the relationship between the median time to tumor progression )(mediant  and the 
hazard rateλ  is 
  5.0(median).t =−λe   (6) 
To get a simple relationship we rearrange formula (6) to get  
  
(median)t
2ln=λ   (7) 
 
By using the corresponding median time )(mediant  to tumor progression in formula (7), 
we may obtain the hazard rateλ  for each group, which is 058.012/2ln ==controlλ  for 
control group and 039.018/2ln ==treatmentλ  for treatment group. Hence, in our study 
the true hazard ratio is 672.0
058.0
039.0 ==
control
treatment
λ
λ
. Using the formula (5) we may 
generate the original times to tumor progression for each group through (8) and (9). 
(Appendix 6.3 shows the results of the times to tumor progression which were known 
from the simulated data) 
  Control group  
058.0
)1ln(
)(
i
icontrol
U
x
−−=  (8) 
Treatment group 
039.0
)1ln(
)(
i
itreatment
U
x
−−=  (9) 
 
In order to obtain 80% power and 5% for the significance level, the sample size of this 
trial requires 150 subjects per treatment group (the total sample size is 300). The sample 
size calculation is based on using the exponential distribution with a set accrual time 
(patients being uniformly recruited during this period) and a fixed follow-up time (in 
order to allow the last subject recruited to have sufficient time to experience an event). 
If θ  is the hazard ratio then the number of events required (assuming equal sized 
group) is given by formula (S Piantadosi, 1997) 
 
  2212/1 )/(ln)(4 θβα −− Ζ+Ζ=eventn   (10) 
In our case 84.0,96.1,667.0
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required is 
  2.191
)667.0(ln
36.31
2 ==eventn  
 
Figure 2.1 Example of accrual and follow-up time 
 
Accrual Period 
Start    Stop      Follow-up 
  Enter     ( )()( fuacc tt + - x) 
 
0   x    )(acct        )()( fuacc tt +  
 
When the accrual time is )(acct  and subjects are uniformly accrued during this period 
(Figure 2.1), we know a subject enters the study at the time point x( x ~ U[0, )(acct ]), 
the probability of the subject enters the study at the time point x  is )(/1 acct . When the 
follow-up time is )( fut  and the total period of study is =+ )( fuacct )()( fuacc tt + , the 
subjects entering the study at its commencement could have a maximum follow-up time 
of )( fuacct +  and those subjects entering at )(acct  would have a follow-up time of )( fut . 
The probability of no event occurring at the time x  is: 
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When xttu fuacc −+= )()( , the survival function is set as ( ) ( )uSxttS fuacc =−+ )()( . 
Since dudx −= , when )()()()( ,;,0 fuaccfuacc tutxttux ==+==  then : 
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Hence, the formula (11) is transferred into formula (12): 
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The survival function ( )uS at any time point u is the reverse cumulative distribution 
function of (2), which is ( ) ueuS ⋅−= λ .  
Then, 
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Hence, the probability of at least one event occurring in the control group is given by:  
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Similarly the probability of at least one event occurring in the treatment group is given 
by: 
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As we know  
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By using formula (15) and (16) we obtain the probability of an event occurring in the 
control group and treatment group 
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The sample size is required 
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So the sample size of 300 for the trial is sufficient. 
 
To capture the information of time to tumor progression, whether censored or not, it is 
necessary to record data for each individual subject, which includes the event time and 
its corresponding censoring indicator (whether the event time records the interval to an 
event or to a censored point). The definition and calculation of the relevant variables 
used in this study are shown as below: 
 
z Entry time 
The overall study period for this trial is 42 months (equal to 182 weeks). Within the 
recruitment period of 24 months, the recruitment rate of eligible subjects into this 
study for each group is 150/24 = 6.25/month, which is round at 6 subjects per 
month. We assume subject is recruited in a random order (e.g., the 1st 6 subjects 
enter study in month 1; the 2nd 6 subjects enter study in month 2, etc.) Hence, in 
each group, subjects are recruited until month 25 to obtain the sample size of 150 
for each group. 
 
z Follow-up time 
After month 26, there is a period of additional follow-up lasting to month 42. 
Attached to each subject the follow-up time is (42- entry time) months, e.g., the 1st 
6 subjects entered at the time of month 1 will receive 41 months follow-up, the 2nd 
6 subjects entered in month 2 will receive 40 months follow-up, the last 6 subjects 
recruited in month 25 will have 17 months follow-up, etc. 
 
z The original time to disease progression and its corresponding censoring indicator 
The original times to tumor progression for both control group and treatment group 
can be generated by using the formula (7) and (8). As the study period is 42 months, 
the time to tumor progression for the subject needs to be replaced by the 
corresponding follow-up time if the time to tumor progression is greater than its 
follow-up time, which means this subject will not be observed to have experienced 
tumor progression at the end of study. This subject is censored (a censoring 
indicator is set to the value of zero). If the time to tumor progression is less than or 
equal to the follow-up time, the subject will have experienced tumor progression, 
hence this subject is failed (the censoring indicator is set to the value of one). 
 
z Scanning visit interval 
In this study we assessed the difference of hazard ratios by changing the time 
interval when a CT scan is conducted to every 3,6,9,12 and 15 weeks. For example, 
when the scans occur every 6 weeks until the end of study period (42 months), the 
1st scanning visit is at week 6 after the patient is randomised into the study, the 2nd 
scanning visit is at week 12, and the 30th scanning visit is at week 180 which is the 
end of the study period (182 weeks). Note that there is a gap of two weeks between 
this last scan time and the end point of study period when the scanning visit interval 
is set at every 6 weeks. 
z Interval-censored data 
The example of data with interval censoring in this study is presented in Figure 2.2 
(e.g., the scanning visit interval at every 6 weeks). We record the time to tumor 
progression in the following three ways: (a) at time t0 (beginning of the interval); (b) 
at time t1 (end of the interval); (c) between time t0 and t1 (interval falling).  
- Subject #1: the subject experienced tumor progression at the exact scanning 
visit time, we record this subject’s time to tumor progression at time t0; 
- Subject #2: the time to tumor progression is falling in the time interval of (t0, t1), 
this subject is censored at time t0 at the previous scanning visit but was 
observed to have experienced tumor progression at the current scanning visit. 
We record this subject’s time to tumor progression at time t1; 
- Subject #3: the subject is supposed to have experienced tumor progression at 
week 181, this subject is censored at week180 which is not observed to have 
tumor progression at that time, however, the next scanning visit is at week 186 
which is after the study end point (week 182), in this case, this subject is 
censored before the end of study period but it is failed in the actual study.  
- Subject #4 and #5: these subjects are censored in the actual study and at the last 
scanning visit at week 180 as well, which means that the tumor progression is 
not observed at the end of study. 
 
 
   1      x 
2           x 
3                             x 
4           
5 
                 
Time t0  t1   180   182     186  (weeks) 
 Figure 2.2 Example of date with interval censoring in this study 
3.0 RESULTS 
 
3.1 Comparison of the hazard ratios based on Cox regression model with different 
scanning visit intervals  
 
The Cox regression model in the statistical software STATA is used to produce the 
estimated coefficients. In calculating these parameters, seed was initially set at 300 to 
generate the uniform random data. Running the simulation trials N=100 to obtain the 
corresponding estimated coefficient and its standard error of Cox regression model with 
different scanning visit intervals, to display the results of fitting the model, we obtain 
the estimated hazard ratios, their standard errors and their associated 95% confidence 
intervals through the relationship between the estimated coefficient and the hazard ratio. 
Hence, the estimated hazard ratio is: 
    )ˆexp(β=HR  
The associated 95% confidence intervals of the estimated hazard ratio are: 
    )]ˆ(96.1ˆexp[ ββ SE±  
The standard error of the estimated hazard ratio is obtained using the delta method 
approximation (D W.Hosmer, JR & S Lemeshow, 1999): 
    )ˆ().ˆexp())ˆ(exp()( βββ SESEHRSE ==  
 
Table 3.1 contains the values of the estimated hazard ratio, its standard error and its 
associated 95% confidence intervals for the required models. The comparison graphs 
are presented in Figure 3.1. 
 
 
 
 
 
 
 
Table 3.1 The estimated hazard ratios and 95% confidence intervals for the treatment effect 
based on Cox Regression with different scanning visit interval at every 3,6,9,12 and 15 weeks. 
 
Model Hazard Ratio (SE) 95% CI 
Cox Regression when  
the original times to tumor progression were used 
0.669 (0.0032) (0.662, 0.675) 
Cox Regression when scanning visit interval is at 
every 3 weeks 
0.674 (0.0030) (0.668, 0.680) 
Cox Regression when scanning visit interval is at 
every 6 weeks 
0.679 (0.0031) (0.673, 0.685) 
Cox Regression when scanning visit interval is at 
every 9 weeks 
0.683 (0.0031) (0.677, 0.689) 
Cox Regression when scanning visit interval is at 
every 12 weeks 
0.689 (0.0032) (0.682, 0.695) 
Cox Regression when scanning visit interval is at 
every 15 weeks 
0.692 (0.0033) (0.686, 0.698) 
 Figure 3.1 The graph for the hazard ratios based on Cox Regression with different scanning 
visit interval at every 3,6,9,12 and 15 weeks (N=100). 
Estimated Hazard Ratios and 95% Confidence Intervals
for the Treatment Effect based on Cox Regression
0.660
0.665
0.670
0.675
0.680
0.685
0.690
0.695
0.700
0.705
H
az
ar
d 
R
at
io
HR
Lower 95% CI
Upper 95% CI
           0                     3                     6                    9                    12                   15
weeks
                                                 (Scanning Interval)
          HR=0.672
 Note:  
1. When the scanning visit interval is equal to 0 in the graph, it means the original times to tumor 
progression were fitted into Cox regression model. 
2. The horizontal line at HR=0.672 is the true hazard ratio of 672.0
058.0
039.0 ==
control
treatment
λ
λ
 
3.2 Comparison of the hazard ratios based on interval-censored (IC) proportional 
hazards model with different scanning visit intervals  
 
In order to obtain the hazard ratio using the interval-censored proportional hazards 
model, we created the expanded data set. This data set contained a new variable, which 
was a binary outcome indicator of the censor status in the specified time interval. Table 
3.2 is presented a few specific examples from the expanded data set when the scanning 
visit interval was at every 6 weeks. The first three lines of data in this table represented 
the subject #1 experienced tumor progression between week 12 and week 18. This was 
noted by week=18. This subject contributed three lines of data to the expanded data set. 
The first line corresponds to that this subject had not experienced tumor progression at 
week 6. For this line the interval=1 and binary outcome indicator=0. The second line is 
for the second 6-week period, denoted by interval=2, and had not experienced tumor 
progression with binary outcome indicator=0. The third line is for the third 6-week 
period, the subject had tumor progression corresponding to the interval=3 and binary 
outcome indicator=1. 
 
The second block of 14 lines represented subject #6, who had tumor progression 
between week 78 and week 84. During the first 13 intervals of follow-up, this subject 
had not experienced tumor progression hence the binary outcome indicator =0. The 
value was changed to 1 in the 14th interval, which was indicating the subject 
experienced tumor progression at this interval. 
 
The third block of 20 lines represented subject #89, who did not experienced tumor 
progression at the end of study and kept the binary outcome indicator=0 at 20th interval. 
 
In STATA the expanded data set was performed and fitted the interval-censored 
proportional hazards model with this expanded data set. The simulation trials were 
conducted 100 times when initiating to set seed at 300. We obtained the corresponding 
estimated coefficients at different scanning visit intervals. Table 3.3 is shown the hazard 
ratios and the associated 95% confidence intervals at different scanning visit interval. 
The comparison graph of the hazard ratios is shown in Figure 3.2. 
Table 3.2 Examples of the expanded data set required to fit the interval-censored(IC) 
proportional hazards model with scanning visit interval at every 6 weeks. 
 
sid scanning time (weeks) interval censor binary outcome indicator 
1 18 1 1 0 
1 18 2 1 0 
1 18 3 1 1 
6 84 1 1 0 
6 84 2 1 0 
6 84 3 1 0 
6 84 4 1 0 
6 84 5 1 0 
6 84 6 1 0 
6 84 7 1 0 
6 84 8 1 0 
6 84 9 1 0 
6 84 10 1 0 
6 84 11 1 0 
6 84 12 1 0 
6 84 13 1 0 
6 84 14 1 1 
89 120 1 0 0 
89 120 2 0 0 
89 120 3 0 0 
89 120 4 0 0 
89 120 5 0 0 
89 120 6 0 0 
89 120 7 0 0 
89 120 8 0 0 
89 120 9 0 0 
89 120 10 0 0 
89 120 11 0 0 
89 120 12 0 0 
89 120 13 0 0 
89 120 14 0 0 
89 120 15 0 0 
89 120 16 0 0 
89 120 17 0 0 
89 120 18 0 0 
89 120 19 0 0 
89 120 20 0 0 
 
Table 3.3 The estimated hazard ratios and 95% confidence intervals for the treatment effect 
based on interval-censored (IC) proportional hazards model with different scanning visit 
interval at every 3,6,9,12 and 15 weeks. 
 
Model Hazard Ratio (SE) 95% CI 
Cox Regression when  
the original times to tumor progression were used 
0.669 (0.0032) (0.662, 0.675) 
IC Regression when scanning visit interval is at 
every 3 weeks 
0.670 (0.0030) (0.664, 0.676) 
IC Regression when scanning visit interval is at 
every 6 weeks 
0.670 (0.0030) 
 
(0.662, 0.676) 
IC Regression when scanning visit interval is at 
every 9 weeks 
0.669 (0.0035) (0.662, 0.676) 
IC Regression when scanning visit interval is at 
every 12 weeks 
0.670 (0.0034) (0.663, 0.676) 
IC Regression when scanning visit interval is at 
every 15 weeks 
0.670 (0.0034) (0.663, 0.676) 
 
Figure 3.2 The graph for the hazard ratios based on interval-censored(IC) proportional hazards 
model with different scanning visit interval at every 3,6,9,12 and 15 weeks (N=100) 
Estimated Hazard Ratios and 95% Confidence Intervals
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Note:  
1. when the scanning visit interval is equal to 0 week, it means the original times to tumor 
progression were fitted into interval-censored proportional hazards model. 
2. The horizontal line at HR=0.672 is the true hazard ratio of 672.0
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4.0 DISCUSSIONS 
 
In this study we firstly fitted the Cox regression model with data, where the subjects’  
times to tumor progression were recorded as at the time of visit when the CT scan was 
performed with different scanning visit interval at every 3, 6, 9, 12 and 15 weeks. Using 
the scanning visit interval to fit Cox regression model will change the actual time to 
tumor progression forward to the right end of the specific scanning visit interval.  
 
Figure 4.1 shows these changes (circle denoted as censoring and X denoted as failure). 
For example, the subject had actual time to tumor progression at week 25. When the 
scanning visit interval was set at every 3 or 9 weeks, this subject was set to have 
experienced tumor progression at week 27; when the scanning visit interval was set at 
every 6 weeks or 15 weeks, this subject experienced tumor progression at week 30; 
when the scanning visit interval was set at every 12 weeks, they were set to have tumor 
progression at week 36 during the study period. These changes would lead to 
conservative results for the estimation of hazard ratio. Hence, changing the scanning 
visit interval may have impact on recording the time to tumor progression fitted into the 
Cox regression model, and the hazard ratio is affected accordingly. When compared 
with the result of the actual study (Cox regression model when the original times to 
tumor progression were used), the scanning visit interval increases, and the estimated 
hazard ratio becomes conservative (Table 3.1 and Figure 3.1). 
 
 
 
 
 
 
 
 
 Figure 4.1 Example of the changes of recording time to tumor progression in the Cox regression 
model with different scanning visit interval at every 3,6,9,12 and 15 weeks. 
           
        X     actual time to tumor progression (weeks) 
    25 
X             scanning visit interval=3 (weeks) 
24         27              
   X         scanning visit interval=6 (weeks) 
24                 30 
X              scanning visit interval=9 (weeks) 
18                    27 
           X scanning visit interval=12 (weeks) 
24                        36 
   X         scanning visit interval=15 (weeks) 
      15                               30 
 
 
When changing the scanning visit intervals, the number of subjects’ failures 
corresponding to the specific scanning visit interval would change, and the number of 
censored observations changes accordingly. For example, one simulation trial was 
conducted for each scanning visit interval. The number of failures in this data set for the 
corresponding scanning visit interval is presented in Table 4.1. From the results we 
obtained that the numbers of failures and the corresponding censored observations  
changed with the scanning visit intervals. The wider the scanning visit intervals, the less 
number of failures, consequently, the greater number of censored observations. Since 
the last scanning visit interval for the specific subject is outside of the study endpoint, in 
the actual study this subject was failed, however, it was censored in the scanning visit 
interval. The total number of these subjects may change the number of failures in the 
associated model. Hence, there is a bias when we fit the Cox regression with different 
scanning visit intervals. In Figure 3.1 the 95% confidence intervals do not include the 
true hazard ratio of 0.672 for the scanning visit intervals at every 6,9,12 and 15 weeks. 
While compared to the horizontal line at HR=0.672, the bias of the hazard ratio 
increases with increasing scanning visit interval. With the scanning visit interval at 
every 15 weeks the power to detect the hazard ratio of 0.692 is 77%, it decreases when 
compared to the actual study with actual times to tumor progression used, which has 
80% power to detect the hazard ratio of 0.667.  
 
Table 4.1 Example of the number of failures and censored observations in the corresponding 
Cox regression model 
 
Number of  Model 
Failures Censored 
Observations
Cox Regression when the original times to tumor progression are used 207 93 
Cox Regression when scanning visit interval is at every 3 weeks 203 97 
Cox Regression when scanning visit interval is at every 6 weeks 203 97 
Cox Regression when scanning visit interval is at every 9 weeks 202 98 
Cox Regression when scanning visit interval is at every 12 weeks 201 99 
Cox Regression when scanning visit interval is at every 15 weeks 200 100 
 
Secondly we fitted the interval-censored proportional hazards model with different 
scanning visit interval at every 3,6,9,12 and 15 weeks. The hazard ratios were almost 
constant and close to the estimate that was obtained from the actual study data using a 
Cox regression model (Table 3.3) While compared to the horizontal line at HR=0.672, 
the 95% confidence intervals include the true hazard ratio of 0.672 for all scanning visit 
intervals (Figure 3.2). This shows that the use of interval-censored proportional hazards 
model when analysing time to event data at different intervals we obtain more accurate 
estimates of the hazard ratios. 
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6.0 APPENDIX  
Major STATA Programmes used in the project 
 
Appendix 6.1 Simulation based on Cox Regression with scanning visit interval at every 3,6,9,12 
and 15 weeks 
 
set memory 700m 
set seed 300  /*set seed so get same random data in future runs of same program*/ 
 program define sim_Cox, rclass  /*define the program named"sim_Cox"*/ 
 drop _all    /*drop previous data*/ 
 set obs 150    /*change sample size by change set obs*/ 
 count     /*count the total observations*/ 
 generate record=_n   /*assign ID for the observations*/ 
 gen u=uniform()   /*generate uniform random numbers*/ 
 generate svw=(-ln(1-(u))/0.058)*52/12  
    /*generate time to tumor progression in weeks for the control group*/ 
 expand 2   /*use the same uniform random numbers*/ 
 generate sid=_n    /*assign ID for all observations*/ 
 egen treatment=cut(sid),group(2) /*generate treatment variable*/ 
 replace svw=svw*0.058/0.039 if treatment==1 
    /*generate time to tumor progression in weeks for the treatment group*/ 
 egen obs=cut(record),group(25)  
 replace obs=obs+1     /*accrual period is 25 months*/ 
 generate followupW=(42-obs)*52/12  /*follow up time in weeks*/ 
 generate diff_svw=svw-followupW  /*generate Cox censor data*/ 
 generate cox_censor=1 if diff_svw<0 
 replace cox_censor=0 if diff_svw>0 
 replace svw=followupW if cox_censor==0  
  /*recode all subjects who have times>study period 182 weeks*/ 
 
 generate scan_3=svw if mod(svw,3)==0 /*generate scan interval=3 weeks*/ 
 replace scan_3=svw-mod(svw,3) +3 if mod(svw,3)>0   
 generate censor_3=1 if scan_3<followupW /*generate Interval censor data*/ 
 replace censor_3=0 if scan_3>=followupW 
  /*recode all subjects whose scan interval times>180 weeks*/ 
  
 generate scan_6=svw if mod(svw,6)==0  /*generate scan interval= 6 weeks*/ 
 replace scan_6=svw-mod(svw,6)+6 if mod(svw,6)>0 
 generate censor_6=1 if scan_6<followupW 
 replace censor_6=0 if scan_6>=followupW 
 
 generate scan_9=svw if mod(svw,9)==0   /*generate scan interval=9 weeks*/ 
 replace scan_9=svw-mod(svw,9)+9 if mod(svw,9)>0 
 generate censor_9=1 if scan_9<followupW 
 replace censor_9=0 if scan_9>=followupW 
 
 generate scan_12=svw if mod(svw,12)==0  /*generate scan interval=12weeks*/ 
 replace scan_12=svw-mod(svw,12)+12 if mod(svw,12)>0 
 generate censor_12=1 if scan_12<followupW 
 replace censor_12=0 if scan_12>=followupW 
 
 generate scan_15=svw if mod(svw,15)==0  /*generate scan interval=15weeks*/ 
 replace scan_15=svw-mod(svw,15)+15 if mod(svw,15)>0 
 generate censor_15=1 if scan_15<followupW 
 replace censor_15=0 if scan_15>=followupW 
 
 stset svw,failure(cox_censor)    /*Cox Regression*/ 
 stcox treatment 
 return scalar b_Cox=_b[treatment]   /*save results for Cox*/ 
 
 stset scan_3, failure(censor_3) /*Cox Regression when scan interval=3 weeks*/  
 stcox treatment 
 return scalar b_IC_3=_b[treatment]  /*save results for IC_scan_3*/ 
  
 stset scan_6, failure(censor_6) /*Cox Regression when scan interval=6 weeks*/  
 stcox treatment 
 return scalar b_IC_6=_b[treatment]   /*save results for IC_scan_6*/ 
 
 stset scan_9, failure(censor_9) /*Cox Regression when scan interval=9 weeks*/  
 stcox treatment 
 return scalar b_IC_9=_b[treatment]  /*save results for IC_scan_9*/ 
 
 stset scan_12, failure(censor_12) /*Cox Regression when scan interval=12 weeks*/ 
 stcox treatment 
 return scalar b_IC_12=_b[treatment]  /*save results for IC_scan_12*/ 
 
 stset scan_15, failure(censor_15) /*Cox Regression when scan interval=15 weeks*/ 
 stcox treatment 
 return scalar b_IC_15=_b[treatment]  /*save results for IC_scan_15*/ 
end 
simulate "sim_Cox" coef_Cox=r(b_Cox) coef_IC_3=r(b_IC_3) coef_IC_6=r(b_IC_6) 
coef_IC_9=r(b_IC_9) coef_IC_12=r(b_IC_12) coef_IC_15=r(b_IC_15), dots reps(100) 
/*do the simulations, change number of simulations by changing the number of reps*/ 
 
describe 
summarize 
Appendix 6.2 Simulation based on Interval-Censored Proportional Hazards Model with 
scanning visit interval at every 6 weeks (this programme is applied to change the scanning visit 
interval at every 3, 9, 12 and 15 weeks by changing the corresponding variables) 
 
clear 
set memory 700m 
set matsize 800 
set seed 300   /*set seed so get same random data in future runs of same program*/ 
 program define sim_IC, rclass   /*define the program named"sim_IC"*/ 
 drop _all    /*drop previous data*/ 
 set obs 150 
 count 
 generate record=_n 
 gen u=uniform()    /*generate uniform random numbers*/ 
 generate svw=(-ln(1-(u))/0.058)*52/12   
 expand 2 
 generate sid=_n 
 egen treatment=cut(sid),group(2) 
 replace svw=svw*0.058/0.039 if treatment==1 
 egen obs=cut(record),group(25) 
 replace obs=obs+1 
 generate followupW=(42-obs)*52/12 
 generate diff_svw=svw-followupW 
 generate cox_censor=1 if diff_svw<0   /*generate Cox censor data*/ 
 replace cox_censor=0 if diff_svw>0 
 replace svw=followupW if cox_censor==0 
 generate scan_6=svw if mod(svw,6)==0   /*generate scanning visit interval at every 6 weeks*/ 
 replace scan_6=svw-mod(svw,6) +6 if mod(svw,6)>0 
 gen count=scan_6/6    /*generate the expnded data set*/ 
 sort sid 
 expand count 
 sort sid 
 quietly by sid: gen intnew = _n   /*generate the binary outcome indicator*/ 
 quietly by sid: gen censor1 = cond( _n == _N, cox_censor, 0) 
 tab intnew,gen(int) 
 
quietly glm censor1 treatment  int1 int2 int3 int4 int5 int6 int7 int8 int9 int10 int11 int12 int13 
int14 int15 int16 int17 int18 int19 int20 int21 int22 int23 int24 int25 int26 int27 int28 int29 
int30, nocons nolog family(bin) link(cl)  /*fitting the binary regression model*/ 
 return scalar b_IC_6=_b[treatment]   /*save results for IC_scan_6*/ 
end 
simulate "sim_IC" coef_IC_6=r(b_IC_6), dots reps(100) 
/*do the simulations, change number of simulations by changing the number of reps*/ 
summarize 
Appendix 6.3 The summary results of the failure times simulated using formula (8) and (9) for 
control group and treatment group 
Note: )(7.74)12/52(
058.0
11 weeksMean
control
control =×== λ  
  )(1.111)12/52(
039.0
11 weeksMean
treatment
treatment =×== λ  
Simulation Group Mean SD Min Max 
Control group 79.196 78.862 0.250 388.476 
1 Treatment group 117.778 117.282 0.371 577.733 
Control group 70.263 77.684 0.966 563.496 
2 Treatment group 104.493 115.530 1.437 838.020 
Control group 79.928 76.249 0.017 344.940 
3 Treatment group 118.867 113.396 0.025 512.988 
Control group 67.284 59.715 0.239 252.934 
4 Treatment group 100.064 88.807 0.355 376.159 
Control group 70.322 77.055 0.024 498.110 
5 Treatment group 104.581 114.594 0.036 740.779 
Control group 73.573 74.216 0.252 416.855 
6 Treatment group 109.417 110.373 0.374 619.939 
Control group 76.011 67.274 0.073 309.804 
7 Treatment group 113.042 100.048 0.109 460.734 
Control group 75.427 84.330 0.069 468.221 
8 Treatment group 112.174 125.415 0.102 696.329 
Control group 74.874 71.898 0.506 397.778 
9 Treatment group 111.351 106.925 0.752 591.568 
Control group 86.398 80.876 1.115 374.290 
10 Treatment group 128.490 120.277 1.659 556.637 
Control group 69.773 68.631 0.017 553.732 
11 Treatment group 103.764 102.067 0.025 823.499 
Control group 68.836 71.663 0.097 374.506 
12 Treatment group 102.372 106.576 0.144 556.957 
Control group 77.470 69.183 1.445 319.165 
13 Treatment group 115.211 102.887 2.149 474.655 
Control group 73.005 71.506 0.827 474.386 
14 Treatment group 108.571 106.343 1.230 705.497 
Control group 86.627 89.793 0.019 674.852 
15 Treatment group 128.830 133.539 0.028 1003.626 
Control group 84.201 87.315 0.010 586.140 
16 Treatment group 125.223 129.854 0.015 871.696 
Simulation Group Mean SD Min 
 
Max 
Control group 80.841 78.339 0.618 479.174 
17 Treatment group 120.225 116.505 0.919 712.617 
18 Control group 76.182 78.430 1.872 508.018 
Treatment group 113.296 116.640 2.783 755.514 
Control group 71.778 69.546 1.118 356.336 
19 Treatment group 106.747 103.428 1.663 529.936 
Control group 83.181 83.302 0.567 483.499 
20 Treatment group 123.705 123.884 0.844 719.050 
Control group 71.259 79.991 0.306 639.630 
21 Treatment group 105.974 118.961 0.454 951.244 
Control group 83.993 76.125 1.081 338.657 
22 Treatment group 124.912 113.211 1.607 503.644 
Control group 71.417 63.821 0.599 437.507 
23 Treatment group 106.210 94.913 0.891 650.652 
Control group 85.362 82.536 0.145 444.303 
24 Treatment group 126.949 122.746 0.215 660.758 
Control group 74.875 69.847 0.314 386.859 
25 Treatment group 111.352 103.875 0.467 575.329 
Control group 78.113 84.541 0.316 534.308 
26 Treatment group 116.168 125.728 0.470 794.612 
Control group 74.208 69.336 0.054 342.025 
27 Treatment group 110.360 103.115 0.080 508.653 
Control group 78.562 83.984 0.095 643.718 
28 Treatment group 116.836 124.899 0.141 957.324 
Control group 82.924 98.018 0.046 683.498 
29 Treatment group 123.322 145.770 0.069 1016.484 
Control group 77.228 77.756 0.521 501.544 
30 Treatment group 114.852 115.637 0.775 745.886 
Control group 66.840 83.068 0.017 508.584 
31 Treatment group 99.403 123.537 0.025 756.356 
Control group 65.944 67.863 0.495 296.828 
32 Treatment group 98.071 100.924 0.737 441.436 
Control group 80.004 79.333 0.138 557.588 
33 Treatment group 118.980 117.982 0.205 829.234 
Control group 69.518 66.809 0.533 304.572 
34 Treatment group 103.386 99.357 0.792 452.954 
Control group 72.108 72.039 0.018 423.204 
35 Treatment group 107.238 107.135 0.027 629.381 
Control group 62.300 53.560 0.426 221.991 
36 Treatment group 92.651 79.654 0.633 330.140 
 
Simulation Group Mean SD Min Max 
Control group 76.427 79.742 0.235 630.445 
37 Treatment group 113.661 118.591 0.349 937.585 
Control group 75.639 71.910 1.802 333.211 
38 Treatment group 112.489 106.943 2.679 495.544 
Control group 70.297 67.285 0.170 423.471 
39 Treatment group 104.544 100.065 0.253 629.777 
Control group 67.332 69.443 0.297 367.117 
40 Treatment group 100.135 103.275 0.442 545.969 
Control group 79.374 66.538 0.027 355.270 
41 Treatment group 118.044 98.953 0.040 528.351 
Control group 73.322 78.681 0.578 404.618 
42 Treatment group 109.044 117.012 0.860 601.739 
Control group 85.996 94.843 0.832 528.002 
43 Treatment group 127.891 141.048 1.238 785.233 
Control group 69.948 66.073 0.120 366.515 
44 Treatment group 104.025 98.262 0.178 545.074 
Control group 72.756 67.026 0.969 404.903 
45 Treatment group 108.201 99.679 1.441 602.163 
Control group 79.088 84.946 0.803 508.102 
46 Treatment group 117.618 126.330 1.195 755.639 
Control group 72.964 71.024 0.911 385.948 
47 Treatment group 108.510 105.626 1.355 573.974 
Control group 68.363 74.839 0.200 506.401 
48 Treatment group 101.668 111.298 0.297 753.109 
Control group 80.284 85.301 0.080 515.415 
49 Treatment group 119.396 126.857 0.120 766.515 
Control group 86.868 110.809 0.141 840.253 
50 Treatment group 129.188 164.792 0.210 1249.607 
Control group 74.134 70.917 1.151 324.308 
51 Treatment group 110.251 105.466 1.712 482.304 
Control group 83.406 77.948 0.443 390.064 
52 Treatment group 124.040 115.923 0.659 580.096 
Control group 63.958 69.680 0.310 440.826 
53 Treatment group 95.117 103.626 0.462 655.588 
Control group 77.633 80.048 0.723 409.157 
54 Treatment group 115.454 119.046 1.075 608.491 
Control group 72.773 67.736 0.148 329.409 
55 Treatment group 108.226 100.735 0.220 489.891 
Control group 74.850 69.062 0.144 367.784 
56 Treatment group 111.315 102.707 0.214 546.961 
 
Simulation Group Mean SD Min Max 
Control group 76.844 79.683 0.102 416.138 
57 Treatment group 114.280 118.503 0.152 618.872 
Control group 82.858 89.985 0.456 488.928 
58 Treatment group 123.225 133.824 0.678 727.124 
59 Control group 74.157 79.545 0.333 605.078 
Treatment group 110.284 118.298 0.495 899.859 
Control group 68.327 66.743 0.217 479.250 
60 Treatment group 101.615 99.259 0.322 712.730 
Control group 85.271 82.819 1.293 474.838 
61 Treatment group 126.813 123.167 1.922 706.170 
Control group 75.237 73.147 0.202 349.057 
62 Treatment group 111.891 108.783 0.301 519.111 
Control group 67.644 63.609 0.085 358.815 
63 Treatment group 100.598 94.598 0.126 533.622 
Control group 71.008 75.003 0.167 366.527 
64 Treatment group 105.602 111.543 0.248 545.091 
Control group 75.041 80.682 0.068 367.599 
65 Treatment group 111.600 119.989 0.101 546.685 
Control group 73.488 71.673 0.146 352.680 
66 Treatment group 109.290 106.591 0.217 524.498 
Control group 85.618 75.102 0.415 380.927 
67 Treatment group 127.329 111.691 0.618 566.507 
Control group 80.438 85.819 1.501 470.673 
68 Treatment group 119.625 127.628 2.232 699.975 
Control group 74.753 80.953 0.346 467.006 
69 Treatment group 111.172 120.392 0.514 694.522 
Control group 74.716 80.600 0.470 498.299 
70 Treatment group 111.117 119.866 0.698 741.060 
Control group 62.245 57.833 0.200 244.447 
71 Treatment group 92.569 86.008 0.297 363.537 
Control group 66.688 65.514 0.116 392.603 
72 Treatment group 99.177 97.431 0.173 583.871 
Control group 76.211 75.264 0.097 449.978 
73 Treatment group 113.340 111.931 0.144 669.198 
Control group 74.658 65.242 1.426 332.546 
74 Treatment group 111.029 97.026 2.121 494.556 
Control group 76.528 82.179 0.704 358.850 
75 Treatment group 113.811 122.215 1.047 533.674 
Control group 70.929 67.926 0.233 352.743 
76 Treatment group 105.484 101.018 0.347 524.592 
 
Simulation Group Mean SD Min Max 
Control group 69.340 63.837 0.107 425.971 
77 Treatment group 103.121 94.937 0.159 633.496 
Control group 66.788 57.875 0.665 284.417 
78 Treatment group 99.326 86.070 0.989 422.980 
Control group 73.599 71.591 0.753 331.062 
79 Treatment group 109.455 106.468 1.119 492.348 
Control group 75.800 74.871 0.330 424.877 
80 Treatment group 112.728 111.346 0.491 631.868 
Control group 71.802 80.462 0.651 582.252 
81 Treatment group 106.782 119.662 0.968 865.913 
Control group 79.284 72.572 2.379 332.991 
82 Treatment group 117.909 107.928 3.537 495.218 
Control group 82.525 86.377 0.283 533.147 
83 Treatment group 122.729 128.458 0.421 792.885 
Control group 80.661 86.342 0.790 454.368 
84 Treatment group 119.958 128.406 1.175 675.727 
Control group 74.260 63.361 2.403 277.752 
85 Treatment group 110.438 94.229 3.574 413.067 
Control group 72.538 70.563 0.349 416.641 
86 Treatment group 107.877 104.940 0.519 619.620 
Control group 71.643 67.247 1.852 291.207 
87 Treatment group 106.546 100.009 2.754 433.076 
Control group 78.215 70.138 0.595 349.010 
88 Treatment group 116.319 104.309 0.886 519.040 
Control group 82.109 74.843 0.476 387.498 
89 Treatment group 122.111 111.305 0.708 576.280 
Control group 66.363 68.033 0.672 410.685 
90 Treatment group 98.694 101.177 0.999 610.763 
Control group 71.660 65.195 1.890 358.646 
91 Treatment group 106.571 96.956 2.811 533.371 
Control group 62.962 66.812 1.020 392.721 
92 Treatment group 93.635 99.361 1.517 584.046 
Control group 82.903 79.088 0.137 474.513 
93 Treatment group 123.292 117.618 0.204 705.687 
Control group 72.186 78.604 0.191 520.547 
94 Treatment group 107.353 116.898 0.284 774.147 
Control group 63.984 65.105 1.550 367.117 
95 Treatment group 95.156 96.823 2.305 545.969 
Control group 68.950 67.368 1.164 451.675 
96 Treatment group 102.541 100.189 1.732 671.722 
 
Simulation Group Mean SD Min Max 
Control group 67.768 66.162 0.126 393.975 
97 Treatment group 100.783 98.395 0.187 585.912 
Control group 89.914 86.512 0.539 461.968 
98 Treatment group 133.719 128.659 0.802 687.029 
Control group 72.783 74.115 0.003 450.324 
99 Treatment group 108.242 110.223 0.005 669.713 
100 Control group 72.127 80.091 0.248 412.516 
Treatment group 107.266 119.110 0.369 613.486 
 
 
